In the recent past, the **bio-tech industry,** specifically **Bayer stocks**, have experienced drastic variations. This volatility is caused by several events, the most significant being the defeat in the **Monsanto Appeal**, trigger of tremendous **share growth**. On top of that, the failed **asundexian trial** led to a severe drop in shares to an 18-year low. Following this, Bayer had to deal with increased challenges related to **Weedkiller,** Roundup, which led the shares to slump again after losing a notable **$2.25 billion trial**. This series of events resulted in Bayer's stock sinking, marking its worst performance ever.
Additionally, **Goldman Sachs** has chosen to remain neutral towards the **Bayer stock** and announcing a €31 target, presenting a doubtful stance towards Bayer's future performance. The firm remains a topic of speculation and setback as it continues to handle the fallout from the **Roundup Woes** and potential restructuring plans. According to Morgan Stanley, the future does not look bright for Bayer as it continues with **legal woes** and an expected drop in profit.
On a positive note, Bayer acquired **BridgeBio's** cardiovascular drug and topped its Q4 earnings shutting down any hopes of a break-up.
BAYER Stocks News Analytics from Tue, 26 Sep 2023 07:00:00 GMT to Mon, 01 Jul 2024 07:00:00 GMT -
Rating -7
- Innovation -6
- Information 4
- Rumor -7
